Quadrant Capital Group LLC Castle Biosciences Inc Transaction History
Quadrant Capital Group LLC
- $3 Billion
- Q3 2025
A detailed history of Quadrant Capital Group LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Quadrant Capital Group LLC holds 336 shares of CSTL stock, worth $11,239. This represents 0.0% of its overall portfolio holdings.
Number of Shares
336Holding current value
$11,239% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding CSTL
# of Institutions
185Shares Held
27MCall Options Held
42.2KPut Options Held
9.3K-
Black Rock Inc. New York, NY3.04MShares$102 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$72.7 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.79MShares$60 Million0.02% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.52MShares$50.7 Million2.16% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.47MShares$49.3 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $880M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...